AbCellera Biologics Inc. (ABCL) is priced at $43.88 after the most recent trading session. At the very opening of the session, the stock price was $39.90 and reached a high price of $44.9899, prior to closing the session it reached the value of $39.95. The stock touched a low price of $39.72.
Recently in News on January 5, 2021, 2020 Canadian IPO mixed results – number (77) down, amount ($5.55B) up driven by PE-backed IPOs. While the US initial public offering (IPO) and special purpose acquisition corporation (SPAC) market experienced an unprecedent boom in 2020, Canadian IPO market continued to struggle with mixed results. You can read further details here
Gold bugs are shouting from the rooftops in excitement, but that doesn’t mean you rush out and just buy any gold stock…That’s why we laid out The 2021 Ultimate Gold Portfolio – to dissect the treasure from the trash.
Price records that include history of low and high prices in the period of 52 weeks can tell a lot about the stock’s existing status and the future performance. Presently, AbCellera Biologics Inc. shares are logging -38.98% during the 52-week period from high price, and 20.98% higher than the lowest price point for the same timeframe. The stock’s price range for the 52-week period managed to maintain the performance between $36.27 and $71.91.
The company’s shares, operating in the sector of Healthcare managed to top a trading volume set approximately around 1911485 for the day, which was evidently higher, when compared to the average daily volumes of the shares.
When it comes to the year-to-date metrics, the AbCellera Biologics Inc. (ABCL) recorded performance in the market was 9.05%. At the time of this writing, the total market value of the company is set at 11.54B, as it employees total of 174 workers.
Analysts verdict on AbCellera Biologics Inc. (ABCL)
During the last month, 1 analysts gave the AbCellera Biologics Inc. a BUY rating, 0 of the polled analysts branded the stock as an OVERWEIGHT, 0 analysts were recommending to HOLD this stock, 0 of them gave the stock UNDERWEIGHT rating, and 0 of the polled analysts provided SELL rating.
Total Debt to Equity Ratio (D/E) can also provide valuable insight into the company’s financial health and market status. The debt to equity ratio can be calculated by dividing the present total liabilities of a company by shareholders’ equity. Debt to Equity thus makes a valuable metrics that describes the debt, company is using in order to support assets, correlating with the value of shareholders’ equity The total Debt to Equity ratio for ABCL is recording 0.31 at the time of this writing. In addition, long term Debt to Equity ratio is set at 0.27.
AbCellera Biologics Inc. (ABCL): Technical Analysis
In the last 20 days, the company’s Stochastic %K was 21.24% and its Stochastic %D was recorded 9.51%.
Let’s take a glance in the erstwhile performances of AbCellera Biologics Inc., multiple moving trends are noted. Year-to-date Price performance of the company’s stock appears to be pessimistic, given the fact the metric is recording 9.05%. The shares increased approximately by 10.78% in the 7-day charts and went up by -25.50% in the period of the last 30 days.